Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

This study is testing a cutting-edge immune cell therapy called UCAR-T (universal CAR-T cells) that targets the CD19 and BCMA proteins found on immune cells that drive certain autoimmune nerve diseases. Unlike conventional CAR-T made from a patient's own cells, UCAR-T cells come from donor cells engineered in a lab, allowing faster availability. The diseases targeted include neuromyelitis optica (NMO), myasthenia gravis, multiple sclerosis, autoimmune encephalitis, and CIDP. **You may be eligible if...** - You are 18 or older - You have been diagnosed with one of these autoimmune nerve conditions: NMOSD, myasthenia gravis, multiple sclerosis, autoimmune encephalitis, or CIDP - Your disease has relapsed or not responded to previous treatments - Your blood tests show the presence of CD19 or BCMA proteins on your B cells - You are using reliable contraception **You may NOT be eligible if...** - You have a history of severe drug allergies - You have had cancer in the last 5 years - You have significant heart problems - You have active hepatitis B, hepatitis C, HIV, or syphilis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.